MX9702303A - Composiciones que contienen por lo menos un glucocorticoide en combinacion con un agente tensioactivo pulmonar para el tratamiento de sindromes de sufrimiento respiratorio infantil y sindrome de sufrimiento respiratorio agudo. - Google Patents

Composiciones que contienen por lo menos un glucocorticoide en combinacion con un agente tensioactivo pulmonar para el tratamiento de sindromes de sufrimiento respiratorio infantil y sindrome de sufrimiento respiratorio agudo.

Info

Publication number
MX9702303A
MX9702303A MX9702303A MX9702303A MX9702303A MX 9702303 A MX9702303 A MX 9702303A MX 9702303 A MX9702303 A MX 9702303A MX 9702303 A MX9702303 A MX 9702303A MX 9702303 A MX9702303 A MX 9702303A
Authority
MX
Mexico
Prior art keywords
acyloxysilane
foaming
containing silicone
silicone materials
bifunctionally
Prior art date
Application number
MX9702303A
Other languages
English (en)
Other versions
MXPA97002303A (es
Inventor
Paul-Georg Germann
Klaus Eistetter
Ulrich Kilian
Original Assignee
Byk Gulden Lomberg Chem Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chem Fab filed Critical Byk Gulden Lomberg Chem Fab
Publication of MXPA97002303A publication Critical patent/MXPA97002303A/es
Publication of MX9702303A publication Critical patent/MX9702303A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)

Abstract

Se describen composiciones novedosas para el tratamiento de IRDS y ARDS, que contienen por lo menos un glucocorticoesteroide y un agente tensioactivo pulmonar. La duracion del tratamiento y la mortalidad asociada con esos síndromes pueden reducirse significativamente con las composiciones novedosas propuestas.
MX9702303A 1994-09-28 1995-09-27 Composiciones que contienen por lo menos un glucocorticoide en combinacion con un agente tensioactivo pulmonar para el tratamiento de sindromes de sufrimiento respiratorio infantil y sindrome de sufrimiento respiratorio agudo. MX9702303A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4434629A DE4434629C1 (de) 1994-09-28 1994-09-28 Zusammensetzungen zur Behandlung von IRDS und ARDS
DEP4434629.8 1994-09-28
PCT/EP1995/003816 WO1996009831A2 (de) 1994-09-28 1995-09-27 Zusammensetzungen zur behandlung von irds und ards, die mindestens ein glucocorticosteroid in kombination mit einem lungen surfactant enthalten

Publications (2)

Publication Number Publication Date
MXPA97002303A MXPA97002303A (es) 1997-06-01
MX9702303A true MX9702303A (es) 1997-06-28

Family

ID=6529394

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9702303A MX9702303A (es) 1994-09-28 1995-09-27 Composiciones que contienen por lo menos un glucocorticoide en combinacion con un agente tensioactivo pulmonar para el tratamiento de sindromes de sufrimiento respiratorio infantil y sindrome de sufrimiento respiratorio agudo.

Country Status (26)

Country Link
US (1) US5891844A (es)
EP (1) EP0783314B1 (es)
JP (1) JP4425991B2 (es)
KR (1) KR100365030B1 (es)
CN (1) CN1100542C (es)
AT (1) ATE241372T1 (es)
AU (1) AU705099B2 (es)
BG (1) BG62556B1 (es)
CA (1) CA2201377C (es)
CZ (1) CZ292846B6 (es)
DE (2) DE4434629C1 (es)
DK (1) DK0783314T3 (es)
EE (1) EE03422B1 (es)
ES (1) ES2201120T3 (es)
FI (1) FI118886B (es)
HK (1) HK1003869A1 (es)
HU (1) HU226958B1 (es)
MX (1) MX9702303A (es)
NO (1) NO313405B1 (es)
NZ (1) NZ294587A (es)
PL (1) PL187496B1 (es)
PT (1) PT783314E (es)
RU (1) RU2157222C2 (es)
SK (1) SK284446B6 (es)
UA (1) UA43378C2 (es)
WO (1) WO1996009831A2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
AU734122B2 (en) * 1997-02-17 2001-06-07 Takeda Gmbh Compositions for the treatment of ARDS or IRDS containing 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4- (difluoromethoxy)benzamide and lung surfactant
US7122344B2 (en) 1997-05-28 2006-10-17 Claragen, Inc. Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
US20060281681A1 (en) 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
CN1194833A (zh) * 1997-10-08 1998-10-07 刘柏宏 肺活素
US6858223B2 (en) 1998-06-23 2005-02-22 Altana Pharma Ag Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS)
CA2372558A1 (en) * 1999-06-11 2000-12-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c)
EP1216052A1 (en) 1999-09-16 2002-06-26 Byk Gulden Lomberg Chemische Fabrik GmbH Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
DE19957898A1 (de) * 1999-12-01 2001-06-07 Byk Gulden Lomberg Chem Fab Neue Verwendung von Lungensurfactant
EP1276495B1 (en) * 2000-04-12 2006-04-19 ALTANA Pharma AG Use of recombinant pulmonary surfactant for the early treatment of acute pulmonary diseases
DE10018022A1 (de) * 2000-04-12 2001-10-31 Byk Gulden Lomberg Chem Fab Neue Verwendung von Lungensurfactant zur Prophylaxe oder Frühbehandlung von akuten Lungenerkrankungen
US20040254112A1 (en) * 2000-04-12 2004-12-16 Dietrich Hafner Use of pulmonary surfactant for the early treatment of acute pulmonary diseases
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
WO2001085136A2 (en) * 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
US20030099601A1 (en) * 2001-11-27 2003-05-29 Gordon Marc S. Inhalation lung surfactant therapy
WO2003053455A1 (en) * 2001-12-12 2003-07-03 Penn State Research Foundation Surfactant prevention of lung complications from cancer chemotherapy
EP1458360B1 (en) 2001-12-19 2011-05-11 Novartis AG Pulmonary delivery of aminoglycosides
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
JP2006527737A (ja) 2003-06-16 2006-12-07 アルタナ　ファルマ　アクチエンゲゼルシャフト 肺サーファクタントとｐｄｅ５阻害剤とを含有する肺疾病の治療用の組成物
PL1670482T5 (pl) * 2003-09-16 2022-10-03 Covis Pharma Gmbh Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego
US7582312B2 (en) 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US7464012B2 (en) * 2004-12-10 2008-12-09 L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude Simplified process simulator
CA2593758A1 (en) 2005-01-06 2006-07-13 Discovery Laboratories, Inc. Surfactant treatment regimen for treating or preventing bronchopulmonary dysplasia
KR100891595B1 (ko) 2005-02-28 2009-04-03 주식회사 케이티앤지 혈액 단백질의 삼출을 감소시키는 조성물
US8221772B2 (en) * 2006-09-19 2012-07-17 Discovery Laboratories Inc. Pulmonary surfactant formulations and methods for promoting mucus clearance
EP2022798A1 (en) * 2007-08-09 2009-02-11 CHIESI FARMACEUTICI S.p.A. Synthetic pulmonary surfactant peptides
WO2012077127A1 (en) * 2010-12-10 2012-06-14 Indian Institute Of Technology, Bombay A protein free surfactant composition for pulmonary diseases and a process for preparing the same
WO2013188016A2 (en) 2012-05-04 2013-12-19 Discovery Laboratories, Inc. Surfactant therapy for exposure to ionizing radiation
CN106310280A (zh) * 2016-08-18 2017-01-11 滨州医学院 地瑞那韦增强糖皮质激素抗炎作用的医药新用途
ES2902578T3 (es) * 2016-12-22 2022-03-29 Chiesi Farm Spa Una combinación terapéutica que comprende un tensioactivo pulmonar y un esteroide para el tratamiento de la BPD evolutiva

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4944941A (en) * 1987-08-07 1990-07-31 Genentech, Inc. Methods and compositions for the treatment of lung conditions
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances

Also Published As

Publication number Publication date
EE9700084A (et) 1997-10-15
CN1163571A (zh) 1997-10-29
JP4425991B2 (ja) 2010-03-03
ES2201120T3 (es) 2004-03-16
EP0783314B1 (de) 2003-05-28
EP0783314A2 (de) 1997-07-16
CZ292846B6 (cs) 2003-12-17
HU226958B1 (en) 2010-03-29
NO313405B1 (no) 2002-09-30
RU2157222C2 (ru) 2000-10-10
PL187496B1 (pl) 2004-07-30
KR100365030B1 (ko) 2003-03-10
FI971277A (fi) 1997-05-27
AU705099B2 (en) 1999-05-13
PL319608A1 (en) 1997-08-18
WO1996009831A3 (de) 1996-05-23
CZ94097A3 (en) 1997-09-17
DK0783314T3 (da) 2003-12-01
HUT77931A (hu) 1998-11-30
EE03422B1 (et) 2001-06-15
CN1100542C (zh) 2003-02-05
BG101441A (en) 1997-09-30
AU3742895A (en) 1996-04-19
NZ294587A (en) 1998-07-28
WO1996009831A2 (de) 1996-04-04
US5891844A (en) 1999-04-06
UA43378C2 (uk) 2001-12-17
FI971277A0 (fi) 1997-03-26
CA2201377A1 (en) 1996-04-04
SK284446B6 (sk) 2005-04-01
DE4434629C1 (de) 1996-06-27
CA2201377C (en) 2008-07-29
FI118886B (fi) 2008-04-30
KR970706006A (ko) 1997-11-03
DE59510705D1 (de) 2003-07-03
BG62556B1 (bg) 2000-02-29
SK40197A3 (en) 1998-02-04
JPH10506119A (ja) 1998-06-16
HK1003869A1 (en) 1998-11-13
NO971403D0 (no) 1997-03-25
ATE241372T1 (de) 2003-06-15
NO971403L (no) 1997-04-17
PT783314E (pt) 2003-10-31

Similar Documents

Publication Publication Date Title
MX9702303A (es) Composiciones que contienen por lo menos un glucocorticoide en combinacion con un agente tensioactivo pulmonar para el tratamiento de sindromes de sufrimiento respiratorio infantil y sindrome de sufrimiento respiratorio agudo.
SI0797439T1 (en) Use of pramipexole as a neuroprotective agent
MY113806A (en) Antiparasitic marcfortines and paraherquamides
HUP0004700A3 (en) Thermoplastic mixture containing 1,4-alpha-d-polyglucane, method for making the same and use thereof
EP0412324A3 (en) Aqueous dispersion composition and process of treatment of fibrous materials
NO961476D0 (no) Kjönrök som er gjort kompatibel, samt fremgangsmåte og anvendelse
ZA915142B (en) Process for preparation of beta-lactams
DE59309762D1 (de) Applikationssystem
GR3027657T3 (en) N-alkylthio polyamine derivatives as radioprotective agents
GR3029700T3 (en) Process for foaming acyloxysilane-containing silicone materials
AU6660694A (en) Use of a vinyl lactam derived terpolymer as foaming agent inaerosol foam-forming compositions, and composition thereby obtained
MX9701671A (es) Composiciones elastomericas curables para producirlas.
HUT73207A (en) Composition and process for recycling elastomeric materials vulcanised by sulphur and process for using the composition
AU630815B1 (en) New process for the industrial preparation of 4-chloro-3-sulfamoyl-n-(2,3-dihydro-2-methyl-1h-indol-1-yl) benzamide
AU8876591A (en) Indole-3-methanamines useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents
AP9100296A0 (en) Peptides and analogues and mixtures thereof for detecting antibodies to HTLV-1 and HTLV11 viruses.
PH23173A (en) P-acylaminobenzamides
IL110932A (en) Difluororibosyl amines and azides and process for preparing the same
ES2090170T3 (es) Agente de recubrimiento espermicida.
IL115007A (en) Process for making sulfonyl isocyanates
UA10935C2 (uk) Суміш для будівельhих виробів
FR2703262B1 (fr) Mélanges gazeux.
DK0782456T3 (da) Konjugat bestående af et virksomt materiale og et nativt, ikke-kropsfremmed protein
TW288020B (en) Monoclonal antibodies specific to methamphetamine, hybridoma producing the antibodies, kits containing the antibodies and uses thereof
ZA84293B (en) Bumper